Alteration of thyroid functions in patients with renal cell carcinoma treated with tyrosine kinase inhibitors; Turkish population study.

Background Studies investigated different side effects of TKIs such as hypertension, dermatologic side effects and hormonal changes. Thyroid hormones change is take an interest for last decade and phase 2 and 3 trial result had been analyzed retrospectively for this reason. Method A totally 246 metastatic renal cell carcinoma patients who were treated with TKI included in the study and they recruited from over 10  different oncology clinics. Results In the study 246 mRCC patients included and mean age was 60 (±8), and 183 (74%) of them were male, 63 (24%) of them were female. Following TKI therapy 15 patients (6%) became as a hyperthyroidic, 83 patients (34%) became hypothyroidic and remaining 148 patients had in normal range for TSH levels. When we subgroup the patients according to the TSH change, in 38 patients (15.4%) had THS  decreasing at least 50% from baseline and 128 patients (52%) has elevated THS levels as described previous range. In survival analyses,  became hyperthyroidic patients had significantly longer OS than became hypothyrodic patients (25.4 vs 14 months, P=0.036) but no  significantly differ than remained normothyroidic patients (25.4 vs 18 months, P=0.16). Conclusion patients who had decreasing TSH levels under the treatment of TKI should have significantly higher overall survival but, hypothyroid patients don’t.